$585,000 Grant to Develop New Biomarkers for Brain Cancer, joint effort from IA-Group’s researchers and St Georges, University of London with St George’s University Hospitals NHS Foundation Trust
Image Analysis Group (IA-Group) and St Georges, University of London with St George’s University Hospitals NHS Foundation Trust have been awarded a grant of over $585,000 by Innovate UK to develop novel Magnetic Resonance Imaging (MRI) biomarkers of the most common type of brain tumours to improve patients’ chance of survival.
The glial tumours are the most common type of primary brain tumour. Most of these are malignant tumours and the overall patient survival rates are poor. We recognized that a newly diagnosed glioma may be a slow-growing ‘low-grade’ or a more heterogeneous, highly infiltrative ‘high-grade’. It is crucial at the earliest possible stage to make the the correct diagnosis, so that the most effective treatment can be given.
We hope to use this funding to examine novel ways to accurately establish the scope and infiltration rates into the normal brain tissue. We believe that more accurate delineation of brain tumour margins and quantification of their grade of malignancy will improve patient outcomes through better patient stratification and more precise treatment targeting.
In this projects, we will aim to create an advanced multi-modal Magnetic Resonance Image (MRI) analysis technique for 3D mapping of glioma grade and infiltration patterns, which is integrated into a state-of-the-art cloud based software framework, IA’s DYNAMIKA. This will provide efficient data processing and an interface between MRI scanners and workstations for use in neurosurgical units for image-guided surgery or radiotherapy planning as well as clinical research studies.
Experts envisage improved patient outcomes by its use at key management points:
i) Tumour tissue targeting for diagnostic biopsy
ii) Optimal surgical resection and assessment of residual tumour tissue
iii) Improved radiotherapy by increased tumour dose and reduced brain tissue dose.
This research work will greatly improve on current manual delineation of tumour margins for treatment planning. The newly developed methodology has global potential for other tumour types and imaging methods.
Mark Hinton, CTO of Image Analysis commented, ‘’We are delighted to be working with St. George’s to deliver better treatments for patients. Projects like this are of great importance in bridging the gap between the best of academic research and routine clinical practise. Innovation has always been a core value for IA’s team.’’
About the Partners:
IA-Group is a strategic partner to bio-pharmacutical companies. We bring extensive therapeutic knowledge and regulatory expertise in strategic use of clinical imaging to enhance understanding of the mode of action, to increase the efficiency of clinical decisions and to accelerate drug development. IA‘s operations team leverage our global footprint and the next-generation cloud based proprietry platform Dynamika to de-risk trial execution and to ensure data quality and integrity. Our venture arm pioneer unique targeted investment and risk-sharing models to enable our clients to reach the next value inflection point faster. We fuse decades of theraputic insight and agile culture to meet today’s speed and high standard of therapeutic innovation.
St George’s, University of London, is the UK’s only dedicated university specialising in health and medical teaching and research (http://www.sgul.ac.uk/). St George’s, University of London, is collocated with St George’s University Hospitals NHS Foundation Trust https://www.stgeorges.nhs.uk/).
Innovate UK is the UK’s innovation agency. It works with people, companies and partner organisations to find and drive the science and technology innovations that will grow the UK economy. For further information visit www.innovateuk.gov.uk